SCHEMBL2060894

SCHEMBL2060894

O=S(=O)(CCN1CCCCC1)N(Cc1ccc(OC(F)(F)F)cc1)c1sc2ccccc2c1Cl

nearest known ligand 0.65

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 7/20 0.65
SLC6A4 P31645 4/20 0.41
SLC6A3 Q01959 4/20 0.41
NPY1R P25929 3/20 0.37
DRD2 P14416 2/20 0.37
HTR2A P28223 2/20 0.37
HTR7 P34969 2/20 0.37
HTR6 P50406 2/20 0.37
MAPK1 P28482 1/20 0.37
NR3C1 P04150 1/20 0.36
CCR5 P51681 1/20 0.35
ACP1 P24666 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2061065 0.90 TRPM8 (0.79) TRPM8SLC6A4SLC6A3
SCHEMBL2061248 0.90 TRPM8 (0.65) TRPM8SLC6A4SLC6A3DRD2HTR2A
SCHEMBL2061023 0.89 TRPM8 (0.81) TRPM8SLC6A4SLC6A3
SCHEMBL2061192 0.87 TRPM8 (0.81) TRPM8SLC6A4SLC6A3
SCHEMBL2060729 0.85 TRPM8 (0.53) TRPM8NR3C1
SCHEMBL2060796 0.83 TRPM8 (0.79) TRPM8DRD2HTR2AHTR7HTR6
SCHEMBL2061092 0.82 TRPM8 (0.64) TRPM8DRD2HTR2AHTR7HTR6
SCHEMBL2061009 0.82 TRPM8 (0.78) TRPM8DRD2HTR2AHTR7HTR6
SCHEMBL2060869 0.81 TRPM8 (0.77) TRPM8
SCHEMBL2060842 0.81 TRPM8 (0.77) TRPM8DRD2HTR2AHTR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148422-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-03 US disclosed
US-8148422-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-03 US disclosed
US-8148422-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-03 US disclosed
WO-2010080398-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-07-15 WO disclosed
US-20100160289-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-06-24 US disclosed
US-20100160289-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-06-24 US disclosed
US-20100160289-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160289-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM2, TRPM5 TRPM8 1/4885SLC6A4 635/4885SLC6A3 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.